- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100, Buphenyl (NaPBA)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Stanford, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 60
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Health Behavior, Obesity, Motor Activity
- Interventions
- Mentoring to be Active with Accelerometers, Planning to be Active with Accelerometers
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 14 Years to 64 Years
- Enrollment
- 571 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 20
- States / cities
- Bidwell, Ohio • Chillicothe, Ohio • Coal Grove, Ohio + 13 more
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Interventions
- HPN-100, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 21 more
- Conditions
- Leukemia
- Interventions
- sargramostim, dexamethasone, oral sodium phenylbutyrate
- Biological · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Pseudobulbar Affect (PBA)
- Interventions
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
- Conditions
- Brain Tumor
- Interventions
- Phenylbutyrate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acne Vulgaris
- Interventions
- Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA)
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Boulder, Colorado • Newnan, Georgia + 13 more
- Conditions
- Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
- Interventions
- AMX0035, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cystic Fibrosis
- Interventions
- Ravicti low dose, Placebo
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Pseudobulbar Affect (Involuntary Laughing and/or Crying)
- Interventions
- NUEDEXTA®
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Miami, Florida • Centerville, Ohio
- Conditions
- Beta Thalassemia
- Interventions
- 5-Azacytidine
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
- Interventions
- Ravicti
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Sodium phenylbutyrate
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- sodium phenylbutyrate
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 10
- States / cities
- Iowa City, Iowa • Lexington, Kentucky • Baltimore, Maryland + 7 more
- Conditions
- Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
- Interventions
- sodium phenylbutyrate
- Drug
- Lead sponsor
- Westat
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Stanford, California • St Louis, Missouri • New York, New York + 2 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 12 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- azacitidine, sodium phenylbutyrate
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Stanford, California + 18 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 29 Days to 6 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Portland, Maine + 5 more
- Conditions
- STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder, Developmental and Epileptic Encephalopathy
- Interventions
- Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 0 Months to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • New York, New York
- Conditions
- Wolfram Syndrome
- Interventions
- AMX0035
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Placebo, AMX0035
- Other · Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 23 more
- Conditions
- ALS
- Interventions
- AMX0035
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- AMX0035
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more